Report: Chelsea set ₤ 100m asking price in the middle of Serie A transfer

Chelsea Slap ₤ 100M Price Tag on Nicolas Jackson Amid A/c Milan Interest

Jackson Edges Towards Exit as Milan Circle

Nicolas Jackson’s Chelsea future has been plunged into unpredictability, with air conditioning Milan now reportedly adding the Senegalese striker to their six-man shortlist for a brand-new centre-forward. According to the Daily Mail, the Serie A giants are confident they could entice the 24-year-old to San Siro, especially after his stock has seemingly fallen under Chelsea manager Enzo Maresca.Jackson, who showed up for ₤ 32 million from Villarreal 2 years earlier, now discovers himself behind summer signings Liam Delap and Joao Pedro in the pecking order. With just four goals since the turn of the year and 2 red cards in his last 5 outings– one versus Newcastle in the Premier League and another versus Flamengo in the Club World Cup– his form has actually dipped at an essential point. As reported by Matt Barlow of the Daily Mail,”Nicolas Jackson is on a/c Milan’s six-man shortlist for a new centre forward and the Italians are confident he can be prised away from Chelsea after falling down the chain of command.”Chelsea’s Position: No Fire Sale In spite of the drop in type and prospective determination from the player to move, Chelsea are playing hardball. The

Blues have actually slapped an incredible ₤ 100 million price on Jackson, sending a clear message that they are not in a rush to sell– or going to let him go on the cheap.The club insists they still value his “desire and attitude “, highlighting that he has scored 30 objectives in two years at Stamford Bridge.

Nevertheless, there is a general approval that he has not consistently shown the killer impulse needed to lead the line in the Premier League. “Chelsea insist they are in no rush to sell and value Jackson at ₤ 100m despite the search to find an upgrade,” the Mail reports.

It’s a valuation that may just cool Milan’s interest, particularly with other names on their list.Milan’s Striker Browse Continues Air conditioner Milan, who have a solid history of handling Chelsea in the transfer market, are in need of supports following the exit of Luka Jovic and completion of Tammy Abraham’s loan. The Italian side is stated to have already received “an indicator from intermediaries that Jackson could be lured”by a relocate to Italy, although whether Milan can– or will– match Chelsea’s assessment remains to be seen.Jackson’s Future Hanging in the Balance With Maresca relatively not encouraged by Jackson and the forward himself unsure of his function going forward, the next few weeks might be decisive. Jackson is clearly at a crossroads– still young, still skilled, however at risk of

stagnancy if chances dry up at Stamford Bridge.Our View

— EPL Index Analysis From a Chelsea fan’s point of view, this report might sting a little– not due to the fact that Jackson is irreplaceable, but due to the fact that the situation highlights a continuous concern in the club’s recent transfer method. Nicolas Jackson has been a brilliant trigger sometimes, revealing pace, work rate, and flashes of instinctive completing. Scoring 30 goals in 2 years

is not a bad return by any ways. However 2 red cards in 5 matches and irregular type have made his inconsistency more difficult to ignore.The ₤ 100 million asking cost? That seems more about securing assets than an authentic market appraisal. Fans may value the club taking a company stance, specifically with Financial Fair Play considerations looming large, however they’ll also want reinforcements who can regularly deliver at the highest level.With Liam Delap and Joao Pedro generated– and clearly relied on by Maresca– it feels

like Jackson might be moved on if the ideal bid gets here. Chelsea advocates may feel conflicted. There’s appreciation for Jackson’s mindset, however also a growing sense that he may not be the long-term option. If Milan do use lots of money– even something in the ₤ 60– 70 million variety– many fans would likely support a sale and reinvestment in a more clinical finisher. View publisher imprint Share this article